Soleno Therapeutics(SLNO)
REDWOOD CITY, CABiotechnology
Focus: Soleno Therapeutics is a public biotechnology company focused on small-molecule therapeutics for metabolic diseases, with a commercial-stage product (VYKAT XR) and an active Phase 3 pipeline targeting rare obesity indications.
Profile data last refreshed 8h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Total Funding
$NaNB
Open Jobs
3
Should You Work at Soleno Therapeutics?
AI assessmentSoleno offers rare-disease pedigree and near-term commercial success, but deteriorating unit economics and legal headwinds create material career execution risk.
Why Work Here
- Commercial momentum: $190M revenue in FY 2025 with VYKAT XR in growth phase and LOE protection through 2035, providing stability.
- Rare disease focus: Phase 3 programs in Prader-Willi Syndrome and SH2B1 Deficiency Obesity represent high-value, unmet-need markets with potential for premium pricing.
Data completeness
7/9 — Strong
Company HealthStrong
Pipeline
Late-stage
4 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$190M
Key Products
Growth9.0yr
Help build intelligence for Soleno Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.